

Mr. FINLATOR. I think it is analogous to the Bureau of Narcotics sitting in the Treasury Department having the same problem, sir, as both of us sitting in the Justice Department having that problem.

Mr. HOLIFIELD. The Bureau of Narcotics in the Treasury Department does at this time make use, there is an arrangement, an agreement I suppose between the Secretaries, that they can make use of all of the technical apparatus which you have in HEW. Is that right?

Dr. LEE. Yes, sir. Our people work closely with them and it is, I think, an excellent cooperative relationship.

Mr. HOLIFIELD. Tell me exactly what that arrangement is, because you know there is a great deal of difference between a line of authority and voluntary cooperation.

Dr. LEE. Well, let's take a synthetic, a new synthetic narcotic. This would come in as an investigational new drug from a pharmaceutical company.

Our people would work closely with the Bureau of Narcotics if this is—during this investigational period.

Chairman BLATNIK. Doctor, just to stop you there, who would call your attention to it. Look, there is something funny about this. How do you normally run into use of a new experimental drug or IND?

Dr. LEE. Investigational new drugs come into the Food and Drug Administration regularly for all new drugs that are produced.

Mr. HOLIFIELD. And I suppose if your agents, whether they were narcotic agents or drug abuse agents, if they picked up some new material from one of these people they have arrested, they would refer that, I suppose, for analysis.

Dr. LEE. Then they immediately consult with the people to do this chemical analysis which Mr. Finlator indicated. They carry out the chemical analysis.

Mr. HOLIFIELD. If a narcotic agent picks up, let us say, heroin, does the Narcotic Bureau do their own analysis of that material, or is that referred to HEW for analysis?

Dr. LEE. Mr. Giordano is here and he might answer that question specifically, because I can't answer it.

Mr. HOLIFIELD. Let him arise in his seat, wherever he may be.

Mr. GIORDANO. The Treasury Department has their own chemical laboratories, and we refer all of our seizures to the Treasury Department laboratories.

Mr. HOLIFIELD. So now that is the thing that worries me a little bit, you have got your line of authority there within your own agency. You no longer in Treasury have the need for those laboratories if this group of narcotic agents were transferred from Treasury. They would then have to send the material across agency lines into another agency for analysis. Is that true?

Mr. GIORDANO. For a temporary period of time. But we intend to set up our own laboratory service in the new agency.

Mr. HOLIFIELD. Now this is something new I don't know about. We are talking about this new Bureau in the Department of Justice. We are talking about more than the transfer of enforcement officers then. Are we talking about the transfer of laboratories, in other words, have your complete line agency there?

Mr. FINLATOR. What we were going to do at present, sir, and I might add that this has been worked out between Dr. Goddard and myself and Dr. Stan Yolles and myself, and is an agreement with the